Skip to content
Screener

Corvus Pharmaceuticals CRVS Net gains (losses) on investments

Net gains (losses) on investments at other companies

Nektar Therapeutics logo
Nektar TherapeuticsNKTR
-$1.75M+60.8%
Iovance Biotherapeutics, Inc. logo
Iovance Biotherapeutics, Inc.IOVA
$52K+73.3%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
-$180K-1,536%

Other financials

Income statement

See full
Operating income-$14.9M-49.9%
Net income-$13.7M-190%
EPS (diluted)-$0.15-15.4%

Balance sheet

See full
Cash & equivalents$40.1M+702%
Total debt$834.0K-27.7%
Total equity$240.7M+388%
Total assets$253.2M+326%

Cash flow

See full
Operating cash flow-$10.4M-25.5%
CapEx$91.0K+153%
Free cash flow-$10.5M-26.1%

Valuation

See full
Market cap$1.16B+243%
Enterprise value$1.12B+245%

Returns & leverage

See full
Return on equity-30.5%-12.5pp
Debt / equity0.0×
Current ratio19.8×+14.9×

Where this comes from

Reported directly by Corvus Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromEquityMethodInvestments.

The source filing: Corvus Pharmaceuticals’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:05 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001104659-26-057100
Line itemThree Months Ended / March 31, 2026Three Months Ended / March 31, 2025
Interest income and other expense, net1,784525
Change in fair value of warrant liability25,129
Loss before equity method investment(13,093)15,732
Loss from equity method investment(599)(539)
Net (loss) income$(13,692)$15,193
Net (loss) income per share, basic$(0.15)$0.21
Net loss per share, diluted$(0.15)$(0.13)
Shares used to compute net (loss) income per share, basic89,996,72872,126,496

Item 1. Financial Statements (unaudited)

FAQ

What is Corvus Pharmaceuticals's net gains (losses) on investments?
Corvus Pharmaceuticals (CRVS) reported net gains (losses) on investments of -$599K in Q1 2026.
How has Corvus Pharmaceuticals's net gains (losses) on investments changed year-over-year?
Corvus Pharmaceuticals's net gains (losses) on investments decreased by 11.1% year-over-year, from -$539K to -$599K.
What is the long-term trend for Corvus Pharmaceuticals's net gains (losses) on investments?
Over 4 years (2021 to 2025), Corvus Pharmaceuticals's net gains (losses) on investments has grown at a -20.2% compound annual growth rate (CAGR), from -$4.83M to -$1.96M.
What does net gains (losses) on investments mean?
Realized and unrealized gains/losses on investments removed from operating cash flow since they're investing-related.

Ask your AI about Corvus Pharmaceuticals's net gains (losses) on investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude